Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

146.22 -0.41 (-0.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
55 56 Next >
Peering Into Biogen's Recent Short Interest
 
Via Benzinga
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential. 
Via InvestorPlace
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties. 
Via Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Breaking Down Biogen: 8 Analysts Share Their Views
 
Via Benzinga
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit
The company missed both sales and earnings expectations for the fourth quarter. 
Via Investor's Business Daily
Looking At Biogen's Recent Unusual Options Activity
 
Via Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. 
Via Benzinga
Topics Economy Stocks
Why Is Biogen Stock Trading Lower On Tuesday?
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs. 
Via Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said. 
Via Benzinga
Topics Economy Stocks
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
 
Via Benzinga
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Critical Insights From Biogen Analyst Ratings: What You Need To Know
 
Via Benzinga
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks. 
Via InvestorPlace
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today
 
Via Benzinga
Comparing Biogen With Industry Competitors In Biotechnology Industry
 
Via Benzinga
Biogen to Realign Resources for Alzheimer's Disease Franchise
From Biogen Inc.
Via GlobeNewswire
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and... 
Via Benzinga
AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. 
Via Benzinga
Highlights From the 2024 JPMorgan Health Care Conference
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. 
Via The Motley Fool
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Nice gains could be on the way for three stocks if analysts are right. 
Via The Motley Fool
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. 
Via Benzinga
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. 
Via Benzinga
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.